Regeneron Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR18.27 |
Market Cap |
EUR30.81 B |
Shares Outstanding |
106.14 M |
Public Float |
77.68 M |
Regeneron Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$21.13 |
Market Cap |
$33.66 B |
Shares Outstanding |
107.73 M |
Public Float |
81.09 M |
Regeneron Pharmaceuticals Inc. | |
Stock Exchange | SIX Swiss Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
106.14 M |
Public Float |
77.68 M |
Address |
777 Old Saw Mill River Road Tarrytown New York 10591 United States |
Employees | - |
Website | http://www.regeneron.com |
Updated | 07/08/2019 |
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. |